You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

By Clay Alspach The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA […] ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

A specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving ...

The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...

Researchers in the TB Alliance informed the Union Conference on Lung Health in Copenhagen that Sorbequiline, a new antibiotic ...

Merck , known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, ...

Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.